Business
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas
OncBioMune Signs Letter of Intent to Initiate Phase 2 Trial of ProscaVax for Advanced Prostate Cancer with Urology Clinics of North Texas.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\n\n BATON ROUGE, La., Feb. 05, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (\"OncBioMune\" or the \"Company\"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, is pleased to announce the signing of a Letter of Intent with Urology Clinics of North Texas (UCNT) for the purpose of initiating a Phase 2 Clinical Trial of ProscaVax in advanced prostate cancer patients.  ProscaVax is OncBioMune’s novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).\n Dr. James S. Cochran, M.D., D.A.B.U., F.A.C.S., UCNT Medical Director, has agreed to serve as the trial’s Principal Investigator.  Dr. Cochran has over 30 years of clinical practice experience and has participated in and provided oversight in more than 300 clinical trials. “Ever since I learned of ProscaVax, I have been highly interested in its potential benefit to the thousands of prostate cancer patients with late-stage disease that face a bleak prognosis with negligible therapeutic options,” commented Dr. Cochran.  “Now that I have reviewed the data from the Phase 1 Clinical Trial, I believe this immunotherapy has the potential to be a game-changer in urology.  I am extremely eager to move this trial forward expeditiously to address an area of great unmet medical need.” UCNT is an award-winning organization servicing the Dallas Metroplex area, the fifth most populous area in North America with approximately 6.5 million people in 13 counties.  The organization is comprised of 16 private urology practices and over 40 providers with approximately half a million patients in their database. “We could not be more pleased that Dr. Cochran and the esteemed prostate cancer experts at UCNT have such a strong desire to be a part of the clinical development of ProscaVax; it truly speaks highly of the vaccine’s potential,” said Dr. Jonathan Head, Chief Executive Officer at OncBioMune.  “Given their decades of experience and robust patient population, we expect the mid-stage study to go ver...